Arcus Biosciences

Yahoo Finance • 19 days ago

Here are the most and least likely M&A targets in biotech, according to Truist

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] French biotech (ABVX [https://seekingalpha.com/symbol/ABVX]) has emerged as the most likely acquisition target among biotechs in 2026, significantly o... Full story

Yahoo Finance • 24 days ago

Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference

HAYWARD, Calif., December 18, 2025--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, infla... Full story

Yahoo Finance • 30 days ago

Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak

Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed. Continue Reading... Full story

Yahoo Finance • 2 months ago

Arcus Biosciences prices $250M offering

* Clinical-stage, global biopharmaceutical company Arcus Biosciences (RCUS [https://seekingalpha.com/symbol/RCUS]) priced [https://seekingalpha.com/pr/20287758-arcus-biosciences-announces-pricing-of-250-million-public-offering-of-common-... Full story

Yahoo Finance • 3 months ago

Sector Update: Health Care Stocks Advance Monday Afternoon

Health care stocks rose Monday afternoon, with the NYSE Health Care Index and the Health Care Select PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Stocks making the biggest moves midday: Broadcom, Bloom Energy, Critical Metals, Fastenal and more

Check out some of the companies making the biggest moves midday: Broadcom -- The chipmaker jumped 10% after agreeing with OpenAI to jointly build and deploy custom artificial intelligence accelerators , the first public plan released by th... Full story

Yahoo Finance • 3 months ago

Arcus Biosciences rises on results from domvanalimab cancer study

[Cancer Anatomy] wildpixel/iStock via Getty Images * Arcus Biosciences (NYSE:RCUS [https://seekingalpha.com/symbol/RCUS]) rose after it reported results from mid-stage study of its monoclinical antibody domvanalimab with zimberelimab an... Full story

Yahoo Finance • 5 months ago

Arcus Biosciences’ SWOT analysis: stock’s potential hinges on HIF-2alpha data

Arcus Biosciences, Inc. (NASDAQ:RCUS), a biopharmaceutical company focused on developing innovative cancer therapies, has been garnering significant attention from investors and analysts alike. The company’s stock performance and future pr... Full story

Yahoo Finance • 5 months ago

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per share, beating the consensus of $1.94. Sal... Full story

Yahoo Finance • 5 months ago

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

PEAK-1, a Phase 3 study evaluating casdatifan + cabozantinib in immunotherapy (IO)-experienced ccRCC, and eVOLVE-RCC02, a Phase 1b/3 study sponsored by AstraZeneca evaluating casdatifan + volrustomig in first-line metastatic ccRCC, have be... Full story

Yahoo Finance • 5 months ago

Arcus Biosciences' SWOT analysis: HIF-2alpha program drives stock outlook

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biopharmaceutical company focused on developing innovative cancer therapies, has been garnering attention from investors and analysts alike due to its promising pipeline and recent developments... Full story

Yahoo Finance • 6 months ago

Arcus' pancreatic cancer drug quemliclustat receives FDA orphan status

HAYWARD, Calif. - Arcus Biosciences, Inc. (NYSE:RCUS), a biotechnology company with a strong balance sheet showing more cash than debt according to InvestingPro data, announced Thursday that its investigational CD73 inhibitor quemliclustat... Full story

Yahoo Finance • 6 months ago

Arcus Biosciences February 2025 slides: oncology pipeline progresses despite Q1 miss

Introduction & Market Context Arcus Biosciences (NYSE:RCUS) presented its corporate update on February 25, 2025, showcasing its oncology pipeline and development strategy. The presentation comes at a challenging time for the clinical-stag... Full story

Yahoo Finance • 7 months ago

Arcus Biosciences' SWOT analysis: promising cancer therapy stock faces pivotal year

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biopharmaceutical company focused on developing innovative cancer therapies, stands at a critical juncture in its journey to bring novel treatments to market. With its lead candidate, casdatifa... Full story

Yahoo Finance • 8 months ago

Q1 2025 Arcus Biosciences Inc Earnings Call

Participants Pia Eaves; Vice President of Investor Relations & Strategy; Arcus Biosciences Inc Terry Rosen; Chairman of the Board, Chief Executive Officer, Co-Founder; Arcus Biosciences Inc Richard Markus; Chief Medical Officer; Arcus B... Full story

Yahoo Finance • last year

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif., October 09, 2024--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, to... Full story

Yahoo Finance • last year

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

Facility adds operational flexibility and provides funding for the recently announced Phase 3 PEAK-1 study for casdatifan. $150 million committed, of which $50 million was drawn at closing and the remaining $100 million available at Arcus'... Full story

Yahoo Finance • 2 years ago

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

– Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 – ALAMEDA, Calif. & HAYWARD, Calif., December 04, 2023--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Arcus Biosciences (NYSE: RCUS) today announce... Full story

Yahoo Finance • 2 years ago

Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript

Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Thank you and welcome to the call. Following prepared remarks from the Company, we will open the call for questions. [Operator instructions] T... Full story

Yahoo Finance • 3 years ago

Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update

Four registrational Phase 3 trials evaluating domvanalimab-based combinations are ongoing or expected to start by year-end; Arcus and Gilead Sciences continue to expand their late-stage clinical program for domvanalimab with the goal of es... Full story